Revolutionizing Cancer Therapy with Conditionally Active Biologics

Learn more Play Video

BioAtla® develops novel cancer therapeutics that meet critical needs including improved safety and the treatment of previously undruggable cancers.

Learn more

BioAtla® Enters Into Strategic License And Option Agreement With Pfizer For A New Class Of Antibody Therapeutics

Learn more

We are Hiring!

At BioAtla® we recognize that the success of our business depends on the excellence of our people, and are dedicated to recruiting exceptional talent for our team.

Learn more

BioAtla® and Sinobioway Select First Program for Strategic Collaboration in China Market

Learn more

Conditionally Active Biologics (CAB’s)

BioAtla®’s revolutionary platform for developing conditionally active therapeutics yields antibodies (or other biologics) that can be activated or inactivated under defined physiological conditions.

Learn more

Tumor Microenvironment

Learn more